NVO bounces on mixed news
The intraday bounce comes as bullish narrative pieces about finding growth beyond its biggest drug franchise collide with bearish pressure from a generic maker moving to clear patent hurdles for a copycat version of its flagship weight-loss drug, leaving the stock whipsawing around a slightly negative daily level.
Sources: https://finance.yahoo.com/markets/
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works